IsomAb Expands Clinical Advisory Board

IsomAb Ltd, a biotechnology company based in the UK, has announced the expansion of its Clinical Advisory Board (CAB). This board will provide expert clinical guidance for the company's main programme, which is focused on developing isoform-specific antibody treatments for serious diseases. The CAB is composed of esteemed international experts in vascular surgery and the management of diabetic patients with vascular complications. Several members have recently collaborated on clinical trials related to limb ischaemia, including the PACE PIII trial.

Jackie Turnbull, CEO of IsomAb Ltd, expressed enthusiasm about the board's expansion, stating that it comes at an opportune time as the company continues to generate preclinical data supporting ISM-001. This antibody is designed to restore blood flow in diabetic vascular disease. Turnbull emphasized that the insights and recommendations from the CAB members will be crucial in guiding the clinical trial program.

The Clinical Advisory Board consists of several notable members:

- Prof. Dr. Maarit Venermo, serving as the CAB Chair, is the head of the department of vascular surgery at Helsinki University Hospital. Her research focuses on evaluating the quality of vascular surgical services and international practice variations. She is also the Secretary General of the European Society for Vascular Surgery (ESVS) and has been involved in various national and international committees.

- Prof. Dr. med. Sigrid Nikol has a background in thoracic and cardiovascular surgery and is the Head of the Department of Interventional Angiology at St. Georg Hospital in Hamburg, Germany. She has over 30 years of experience in translational angiogenesis research and has played active roles in numerous clinical trials. She is past-president of the European Society for Vascular Medicine (ESVM) and a member of several professional societies.

- Professor Robert Hinchliffe is a Clinical Professor of Vascular Surgery at Bristol Medical School and the Chair for the Research for Patient Benefit Southwest region. He is an Honorary Consultant Vascular Surgeon in the Bristol, Bath, Weston Vascular Network and has a research interest in diabetes-related complications and peripheral artery disease.

- Marc P. Bonaca, M.D., MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado. He is also the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine. He is a member of several professional organizations, including the Society of Vascular Medicine and the American Heart Association.

- Professor John C. Lantis II, MD, is the site Chief and Professor of Surgery at Mount Sinai West Hospital and the Icahn School of Medicine in New York. He is a senior vascular surgeon and has been a principal investigator on over 70 clinical trials. He is also involved in several professional organizations.

- Joseph L. Mills, M.D., FACS, is a board-certified vascular surgeon in Houston, Texas, specializing in diabetic foot amputation prevention and limb salvage. He has authored nearly 300 peer-reviewed journal articles and book chapters and has been the principal investigator for over 40 clinical trials.

- Professor Michael Edmonds is a Consultant Physician at King's College Hospital in London with a special focus on diabetic foot care. He developed one of the first multi-disciplinary diabetic foot clinics in the world and has received several awards for his work in amputation prevention.

- Professor Stephen Bain is the Clinical Director of the Diabetes Research Unit at Swansea University and Medical Director for Research & Development for Swansea Bay University Health Board. He has been the Chief Investigator for several multi-centre trials investigating novel therapies for diabetes.

IsomAb Ltd was founded in 2022 as a spin-out from the University of Nottingham, with early research conducted at the University of Bristol. The company focuses on developing isoform-specific antibodies for the treatment of life-limiting diseases with peripheral ischaemia.